PTGX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PT

Mkt Cap

$8.34B

Volume

682.78K

Next Earnings

November 5th

Loading chart

PT

PTGXProtagonist Therapeutics, Inc

PTGX

Pay with—

Available Balance0.00

PT

Mkt Cap

$8.84B

Volume

682.78K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should KnowProtagonist Therapeutics has been upgraded to Zacks Rank #1 (Strong Buy) due to rising earnings estimates. The biopharmaceutical company's consensus estimate has increased 44.1% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects improved business fundamentals that could drive near-term stock price appreciation.Zacks Investment Research · Oct 15, 2026

J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?Johnson & Johnson's stock has risen 18.3% in three months, driven by strong Innovative Medicine segment growth (6.2% organic), successful new drug launches (Icotyde, Imaavy, Inlexzo), and progress on talc litigation resolution. The company targets $100 billion in 2026 revenues and expects double-digit growth excluding Stelara impact. However, J&J faces headwinds from Stelara's patent expiration, MedTech slowdown, and upcoming generic competition for other drugs. Despite these challenges, analysts recommend staying invested given the company's diversified portfolio, strong pipeline, and confident guidance.Zacks Investment Research · Sep 18, 2026

Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsightThe ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.GlobeNewswire Inc. · Sep 7, 2026

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightThe polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first new entrant to market this year, potentially reshaping the treatment paradigm beyond current standard therapies like JAKAFI, BESREMi, and PEGASYS.GlobeNewswire Inc. · Apr 22, 2026

This Healthcare Stock Barely Flinches During Market Sell-OffsJohnson & Johnson demonstrates resilience during market downturns, with shares falling less than 2% while the S&P 500 dropped over 7%. The healthcare giant maintains strong fundamentals including 63 consecutive years of dividend increases, $94.2 billion in 2025 revenue (up 6%), and 51 drug approvals last year. However, the stock faces headwinds from tens of thousands of talc-related lawsuits and Medicare drug price negotiations under the Inflation Reduction Act.The Motley Fool · Apr 2, 2026

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVieThe FDA approved Icotyde (icotrokinra), an oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis developed by Johnson & Johnson and Protagonist Therapeutics. The approval triggers a $50 million milestone payment to Protagonist with potential for up to $580 million in additional payments. AbbVie's stock fell 5.20% as analysts view Icotyde as competitive to AbbVie's Skyrizi, though both companies believe oral therapies could expand the overall psoriasis market.Benzinga · Mar 19, 2026

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million ExitHedge fund BVF fully exited its position in Protagonist Therapeutics (PTGX), selling 2.56 million shares worth $170.12 million. Despite the stock rallying 120% over the past year, the fund's exit reflects a disciplined capital rotation strategy following the company's New Drug Application submission for rusfertide in polycythemia vera, marking a shift from clinical-stage risk to regulatory execution risk.The Motley Fool · Feb 25, 2026

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 MillionMoody Aldrich Partners LLC completely sold its entire 35,228 share position in Chart Industries, valued at approximately $5.8 million, reducing its reportable assets to zero in Q3 2025.The Motley Fool · Oct 23, 2025

Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 MillionMoody Aldrich Partners LLC completely sold its entire 53,211 share position in Palomar Holdings for an estimated $8.21 million during Q3 2025, reducing its stake to zero, likely as part of routine portfolio rebalancing.The Motley Fool · Oct 21, 2025

This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can BuyJohnson & Johnson demonstrated strong financial health in Q3, with 7% sales growth, $14.2 billion in free cash flow, and plans to separate its orthopedics business to focus on six priority growth areas. The company remains committed to dividend growth and oncology investments.The Motley Fool · Oct 15, 2025

to start trading

PT

PTGXProtagonist Therapeutics, Inc

PTGX

Pay with—

Available Balance0.00

Your PositionYou don't own any PTGX yet.

Related Tickers

Earnings